Protons inhibitors/activators

Considering the big variety of proton emitters and detectors, it is not difficult to insert such informative molecules as inhibitors, activators, substrate, or ligands into specific sites in proteins, membranes, or nucleic acids and study directly the role of water and proton in biochemistry. 

Cerium conversion solution typically consists of cerium salt such as CeCl3, Ce(N03)3, CeP04, Ce(S04)2, Cc2(S04)3 or Ce(NH4)2(N03)g, and sometimes with additives of other salts such as La(N03)3and Pr(N03)3 [16], Zr0(N03)3 and Nb OyF [17] and A1(N03)3 and Ca(OH)2 [18]. Wetting agents, buffer pH adjustors, corrosion inhibitors, activators and oxidants are always added into the conversion solutions too. When magnesium and its alloys are immersed in the cerium conversion solution and dissolved, the local pH at the metal-solution interface increases resulting from the reduction of proton or dissolved O2 in the solution by the reaction ... 

Proton Pump Inhibitors and Acid Pump Antagonists retinoid X receptor (RXR) and is also activated by various lipophilic compounds produced by the body such as bile acids and steroids. PXR heterodimerized with RXR stimulates the transcription of cytochrome P450 3A monooxygenases (CYP3A) and other genes involved in the detoxification and elimination of the... 

The first compound of this class with inhibitory activity on the enzyme and on acid secretion was the 2-(pyridylmethyl)sulfinylbenzimidazole, timopra-zole, and the fust pump inhibitor used clinically was omeprazole, 2-[[3,5-dimethyl-4-methoxypyridin-2-yl] methylsulfinyl]-5-methoxy- lH-benzimidazole. Omeprazole is an acid-activated prodrug. Omeprazole and the other PPIs are accumulated in the acidic space of the parietal cell due to the pKa of the pyridine nitrogen and these are converted due to protonation of the benzimidazole nitrogen first to a thiol-reactive cationic sulfenic acid and then dehydrated to form the sulfenamide (Fig. 1). These thiophilic cations then bind to luminally... 

Proton Pump Inhibitors and Acid Pump Antagonists. Figure 2 Chemical mechanism of irreversible PPIs. PPIs are accumulated in acidic lumen and converted to active sulfenic acid and/or sulfenamide by acid catalysis. These active forms bind to extracytoplasmic cysteines of the gastric H.K-ATPase [3]. 

The proton pump inhibitors are particularly important in the treatment of Helicobacter pylori in patients with active duodenal ulcers. Helicobacter pylori (H. pylori) has been implicated as a causative organism in a type of chronic gastritis and in a large number of cases of peptic and duodenal ulcers. 

The HIV-1 protease, like other retroviral proteases, is a homodimeric aspartyl protease (see Fig. 1). The active site is formed at the dimer interface, with the two aspartic acids located at the base of the active site. The enzymatic mechanism is thought to be a classic acid-base catalysis involving a water molecule and what is called a push-pull mechanism. The water molecule is thought to transfer a proton to the dyad of the carboxyl groups of the aspartic acids, and then a proton from the dyad is transferred to the peptide bond that is being cleaved. In this mechanism, a tetrahedral intermediate transiently exists, which is nonconvalent and which is mimicked in most of the currently used FDA approved inhibitors. 

As indicated in Fig. 1, nitrogenase can reduce substrates other than Na. In the absence of other reducible substrates it will reduce protons to dihydrogen, but it can also reduce a number of other small triple-bonded substrates, as indicated in Section V,E,1. Large substrates are not reduced efficiently, indicating physical limitations on access to the enzyme s active site. CO is a potent inhibitor of all nitrogenase substrate reductions except that of the proton to Ha. In the presence of CO the rate of electron transfer is generally not inhibited, but all electrons go toward the production of Ha. 

In order to account for the inability of many enzymes to bind the protonated form of the basic inhibitors or permanently cationic ones better than uncharged analogs (for example, yS-o-galactosidase from E. coli, and P-v>-glucosidase from almonds), it was proposed that the enzyme could proton-ate the inhibitor at the active site by a cationic acid (for example, protonated histidine). If proton transfer cannot occur, the attractive forces due to the carboxylate would be canceled by the repulsion from the cationic acid. Experimental evidence for this proposal is, however, still lacking. In fi-D-gn-lactosidase from E. coli, a tyrosine is presumed to be responsible for the protonation of substrates. ... 

ATPase also catalyzed a passive Rb -Rb exchange, the rate of which was comparable to the rate of active Rb efflux. This suggested that the K-transporting step of H,K-ATPase is not severely limited by a K -occluded enzyme form, as was observed for Na,K-ATPase. Skrabanja et al. [164] also described the reconstitution of choleate solubilized H,K-ATPase into phosphatidylcholine-cholesterol liposomes. With the use of a pH electrode to measure the rate of H transport they observed not only an active transport, which is dependent on intravesicular K, but also a passive H exchange. This passive transport process, which exhibited a maximal rate of 5% of the active transport process, could be inhibited by vanadate and the specific inhibitor omeprazole, giving evidence that it is a function of gastric H,K-ATPase. The same authors demonstrated, by separation of non-incorporated H,K-ATPase from reconstituted H,K-ATPase on a sucrose gradient, that H,K-ATPase transports two protons and two ions per hydrolyzed ATP [112]. 

Eradication therapy with a proton pump inhibitor-based three-drug regimen should be considered for all patients who test positive for HP and have an active ulcer or a documented history of either an ulcer or ulcer-related complication. Different antibiotics should be used if a second course of HP eradication therapy is required. 

---